Douglass Winthrop Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Douglass Winthrop Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-10,000	Closed	-$11K	–	261
2019 Q2	$11K	Hold	10,000	–	–	﹤0.01%	258
2019 Q1	$13K	Hold	10,000	–	–	﹤0.01%	240
2018 Q4	$9K	Sell	10,000 -1,430	-13%	-$2.19K	﹤0.01%	243
2018 Q3	$23K	Hold	11,430	–	–	﹤0.01%	252
2018 Q2	$21K	Hold	11,430	–	–	﹤0.01%	286
2018 Q1	$27K	Hold	11,430	–	–	﹤0.01%	268
2017 Q4	$21K	Hold	11,430	–	–	﹤0.01%	239
2017 Q3	$28K	Hold	11,430	–	–	﹤0.01%	248
2017 Q2	$31K	Hold	11,430	–	–	﹤0.01%	242
2017 Q1	$34K	Hold	11,430	–	–	﹤0.01%	241
2016 Q4	$36K	Hold	11,430	–	–	﹤0.01%	238
2016 Q3	$39K	Hold	11,430	–	–	﹤0.01%	240
2016 Q2	$26K	Sell	11,430 -5,715	-33%	-$14K	﹤0.01%	235
2016 Q1	$43K	Sell	17,145 -1,440	-8%	-$3.21K	﹤0.01%	220
2015 Q4	$61K	Hold	18,585	–	–	﹤0.01%	228
2015 Q3	$45K	Buy	+18,585	New	+$48.1K	﹤0.01%	232

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Douglass Winthrop Advisors's LCTX Position: Q3 2019 in Review

Douglass Winthrop Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q3 2019, closing a stake of 10,000 shares — an estimated $11K sold.

Douglass Winthrop Advisors first reported a position in LCTX in Q3 2015 and held it in 16 quarters. The position peaked at $61K in Q4 2015. 96 funds tracked by Wall St. Rank hold LCTX as of Q3 2019.

Douglass Winthrop Advisors reported no remaining Lineage Cell Therapeutics position as of Q3 2019 after selling out during the quarter.
Douglass Winthrop Advisors sold 10,000 Lineage Cell Therapeutics shares in Q3 2019, an estimated $11K.
Douglass Winthrop Advisors first reported a position in Lineage Cell Therapeutics in Q3 2015 and held it in 16 quarters.
Douglass Winthrop Advisors's Lineage Cell Therapeutics position peaked at $61K in Q4 2015.
96 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2019.

Based on Douglass Winthrop Advisors's 13F filing for Q3 2019, filed 8 Oct 2019.